Janux Cash Per Share from 2010 to 2024

JANX Stock  USD 46.39  1.61  3.35%   
Janux Therapeutics Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 4.00 in 2024. During the period from 2010 to 2024, Janux Therapeutics Cash Per Share regression line of annual values had r-squared of  0.49 and arithmetic mean of  1.94. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
7.81592576
Current Value
4
Quarterly Volatility
3.43678988
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 13.1 M, Depreciation And Amortization of 2.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 55.51, Dividend Yield of 0.0 or PTB Ratio of 1.44. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Janux Therapeutics over the last few years. It is Janux Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 8.15 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Janux Cash Per Share Regression Statistics

Arithmetic Mean1.94
Geometric Mean0.09
Coefficient Of Variation176.92
Mean Deviation2.80
Median0.02
Standard Deviation3.44
Sample Variance11.81
Range9.0758
R-Value0.70
Mean Square Error6.47
R-Squared0.49
Significance0
Slope0.54
Total Sum of Squares165.36

Janux Cash Per Share History

2024 4.0
2023 7.82
2022 7.89
2021 9.09
2020 0.19

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 7.82  4.00 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.